|BioCryst Pharmaceuticals Inc -- USA Stock|| |
USD 5.39 0.02 0.37%
VP, General Counsel and Corporate Secretary
Ms. Alane P. Barnes serves as a Vice President, General Counsel, and Corporationrationrate Secretary of BioCryst. She was named Corporationrationrate Secretary in 2007, and has served as Vice President, General Counsel Corporationrationrate Secretary since 2011. She was named as an executive officer in 2013. Ms. Barnes is responsible for all legal affairs of the company including but not limited to all contract negotiations, SEC compliance, corporate governance, IP strategy and management, licensing transactions, government contract management and dispute resolution. She graduated magna cum laude from Cumberland School of Law in 1997 and is a member of Curia Honoris, scholar of merit
Age: 50 VP Since 2013
Barnes received her B.S. in Natural Science with a concentration in biology and chemistry from UAB. Prior to joining the Company, Ms. Barnes worked for the UAB Research Foundation where she managed intellectual property, negotiated license transactions and facilitated the emergence of new companies based on university technology. Prior to employment at the UAB Research Foundation Ms. Barnes practiced corporate law with a prominent law firm in Birmingham, Alabama. Currently, she serves on the Board of the Biotechnology Association of Alabama and has served as a mentor for Alabama Launchpad, a competition created to fuel the development of companies in Alabama.
Alane Barnes Latest Insider Activity
The company has return on total asset (ROA)
of (21.09) %
which means that it has lost $21.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (128.72) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 54.52 M in liabilities with Debt to Equity (D/E) ratio of 54.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioCryst Pharmaceuticals Inc has Current Ratio of 2.48 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. BioCryst Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ exchange.BioCryst Pharmaceuticals Inc (BCRX) is traded on NASDAQ in USA. It is located in NORTH CAROLINA, U.S.A and employs 65 people. BioCryst Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.